Drugs in ATC Class J01ED

Up to Top Level ATC Classes

Up to J - Antiinfectives for systemic use

Up to J01 - ANTIBACTERIALS FOR SYSTEMIC USE

Up to J01E - SULFONAMIDES AND TRIMETHOPRIM

Drugs in ATC Class: J01ED - Long-acting sulfonamides

Tradename	Generic Name
LANTRISUL	trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine)
NEOTRIZINE	trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine)
SULFALOID	trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine)
SULFONAMIDES DUPLEX	sulfadiazine; sulfamerazine

J01ED Market Analysis and Financial Projection

The market for long-acting sulfonamides (ATC Class J01ED) is shaped by clinical utility, evolving antibiotic resistance patterns, and strategic patent activity. These antimicrobials, characterized by a biological half-life ≥35 hours[1][5], are experiencing steady growth due to their dosing advantages and expanding applications in human and veterinary medicine. Below is a detailed analysis of current dynamics:

---

Market Dynamics

Growth Projections and Drivers

• The long-acting sulfonamide market was valued at $1.2 billion in 2022, with projections reaching $1.7 billion by 2030 (CAGR 5.2%)[3]. Alternative estimates suggest a higher valuation of $2.5 billion in 2023, growing to $4.1 billion by 2030 (CAGR 7.2%)[7], reflecting regional variations and therapeutic demand.
• Key growth drivers:
  • Rising antibiotic resistance, particularly in urinary/respiratory infections[3][4].
  • Extended dosing intervals improving patient compliance[1][5].
  • Veterinary applications in livestock management[3][7].

Competitive Landscape

• Dominant players: Pfizer, Sanofi, Roche, and Teva lead production, leveraging slow-release formulations and combination therapies[7].
• Regional demand: The U.S., China, and India drive uptake due to high antimicrobial use and chronic infection rates[3].

Challenges

• Regulatory scrutiny on antibiotic stewardship[4][7].
• Competition from newer antibiotic classes and generic alternatives[7].

---

Patent Landscape

Formulation Innovations

• Injectable compositions: Patents like EP0021847 describe stable aqueous solutions of sulfadimethoxine using 2-pyrrolidone co-solvents (40–65% w/v), enabling prolonged release[9][13].
• Combination therapies: Growing interest in repurposing sulfonamides for rare diseases, e.g., WO/2022/159086 (gemfibrozil + sulfonamides for Krabbe disease)[2].

Strategic Patenting Trends

• Applicant profiles: 41% of rare-disease repurposing patents come from SMEs, while universities contribute 34%. Large pharma accounts for <3%[2].
• Geographic focus: The U.S. and EU dominate filings, contrasting with limited activity from Asian innovators despite strong academic research[2][11].

White Spaces

• Limited recent patents on novel J01ED compounds, with most activity focusing on:
  • Delivery systems: Slow-release formulations[3][9].
  • Adjunct therapies: Combinations with antifungals or antiparasitics[2][5].

---

Future Outlook

The sector will likely prioritize drug-device combinations (e.g., slow-release implants) and repurposing for niche indications (e.g., lysosomal storage disorders)[2][7]. Collaborative models between academia and SMEs may offset big pharma’s limited engagement[2], while emerging markets offer untapped potential despite regulatory hurdles.

Key Insight:
"Long-acting sulfonamides bridge a critical gap in antimicrobial stewardship by reducing dosing frequency, but their future hinges on innovating beyond traditional applications." [3][7]

References

1. https://atcddd.fhi.no/atc_ddd_index/?code=J01ED
2. https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647%2FDRUGREPO.24.1.0012
3. https://www.verifiedmarketreports.com/product/long-acting-sulfonamide-market/
4. https://www.ecdc.europa.eu/sites/default/files/documents/ESAC-Net-archive-report_survey_antimicrobial_prescriptions_eu_hospitals_2009.pdf
5. https://atcddd.fhi.no/atc_ddd_index/?code=J01E&showdescription=yes
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC9138112/
7. https://github.com/nkomdaumis16/Market-Research-Report-List-1/blob/main/long-acting-sulfonamide-market.md
8. https://www.healthybelgium.be/en/medical-practice-variations/medications/antiinfectives-for-systemic-use/antibiotics-periodontology
9. https://patents.google.com/patent/EP0021847A2/en
10. https://atcddd.fhi.no/atc_ddd_index/?code=J01ED01
11. https://ip.com/blog/2025-patent-trends-challenges-and-innovations-shaping-the-future-of-technology/
12. https://papers.ssrn.com/sol3/Delivery.cfm/SSRN_ID3848763_code830407.pdf?abstractid=3660454
13. https://patents.google.com/patent/EP0021847B1/en